All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Data on the development of novel noncationic macrocyclic peptides for inhibiting GTPase KRAS signaling for the potential treatment of cancer were presented by investigators from Merck & Co. Inc.
